drugset
drugset / Trial / NCT03689153

A Study of JNJ-63733657 in Healthy Japanese Participants

NCT03689153 ↗

Phase 1 Completed 24 enrolled Janssen Pharmaceutical K.K.
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of JNJ-63733657 following single ascending intravenous (IV) dose administration in healthy Japanese participants.

Timeline

Start
2018-09-28
Primary completion
2019-07-11
Completion
2019-07-11

Drugs

EvaluationDrugModalityDoseRoute
Subject posdinemab Monoclonal antibody — Intravenous

Indications

No indication recorded.